Drug Injury in the Upper Gastrointestinal Tract: Effects of Alendronate

Gastrointestinal Endoscopy Clinics of North America

Volumn 16, Issue 1, 2006, Pages 99-110

  Khapra, Asma P ^a   Rose, Suzanne ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PROTON PUMP INHIBITOR; RISEDRONIC ACID; SUCRALFATE;

ABDOMINAL PAIN; ANOREXIA; BLEEDING; BONE DENSITY; BONE METASTASIS; BONE MINERALIZATION; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; DUODENITIS; DUODENUM INJURY; DYSPEPSIA; DYSPHAGIA; ENDOSCOPY; EPIGASTRIC DISCOMFORT; EROSIVE GASTRITIS; ESOPHAGITIS; ESOPHAGUS INJURY; ESOPHAGUS ULCER; FOOD AND DRUG ADMINISTRATION; FRAGILITY FRACTURE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; HYPERCALCEMIA; INTESTINE PERFORATION; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; ODYNOPHAGIA; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PEPTIC ULCER; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RABBIT; RAT STRAIN; REVIEW; STOMACH ACID SECRETION; STOMACH INJURY; STOMACH MUCOSA; STOMACH ULCER; THORAX PAIN; UPPER GASTROINTESTINAL TRACT; VOMITING;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DUODENUM; ETIDRONIC ACID; GASTRIC MUCOSA; HUMANS; MODELS, ANIMAL;

EID: 33646082733     PISSN: 10525157     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.giec.2006.01.002     Document Type: Review

References (50)

1. Talley N.J., O'Keefe E.A., Zinsmeister A.R., et al. Prevalence of gastrointestinal symptoms in the elderly: A population-based study. Gastroenterology 102 (1992) 895-901
2. National osteoporosis foundation. Fast facts. Available at:. http://www.nof.org/osteoporosis/diseasefacts.htm Accessed August 2005
3. Sharpe M., Noble S., and Spencer C.M. Alendronate: an update of its use in osteoporosis. Drugs 61 (2001) 999-1039
4. Lufkin E.G., Argueta R., Whitaker M.D., et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 4 (1994) 320-322
5. Graham D.Y. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 47 (2002) 1665-1678
6. Lanza F., Schwartz H., Sahba B., et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 95 (2000) 3112-3117
7. Fleisch H.A. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 29 (1997) 55-62
8. Cryer B., and Bauer D.C. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?. Mayo Clin Proc 77 (2002) 1031-1043
9. Jeal W., Barradell L.B., and McTavish D. Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Drugs 53 (1997) 415-434
10. Boivin G.Y., Chavassieux P.M., Santora A.C., et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27 (2000) 687-694
11. Hosking D., Chilvers C.E., Christiansen C., et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early postmenopausal intervention cohort study group. N Engl J Med 338 (1998) 485-492
12. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group. N Engl J Med 333 (1995) 1437-1443
13. Pols H.A., Felsenberg D., Hanley D.A., et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax international trial study group. Osteoporos Int 9 (1999) 461-468
14. Tucci J.R., Tonino R.P., Emkey R.D., et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101 (1996) 488-501
15. Shiraki M., Kushida K., Fukunaga M., et al. A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal japanese patients with osteoporosis. The alendronate research group. Endocr J 45 (1998) 191-201
16. de Groen P.C., Lubbe D.F., Hirsch L.J., et al. Esophagitis associated with the use of alendronate. N Engl J Med 335 (1996) 1016-1021
17. Ettinger B., Pressman A., and Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 4 (1998) 1377-1382
18. Peter C.P., Kindt M.V., and Majka J.A. Comparative study of potential for bisphosphonates to damage gastric mucosa of rats. Dig Dis Sci 43 (1998) 1009-1015
19. Elliott S.N., McKnight W., Davies N.M., et al. Alendronate induces gastric injury and delays ulcer healing in rodents. Life Sci 62 (1998) 77-91
20. Wallace J.L., Dicay M., McKnight W., et al. N-bisphosphonates cause gastric epithelial injury independent of effects on the microcirculation. Aliment Pharmacol Ther 13 (1999) 1675-1682
21. Blank M.A., Gibson G.W., Myers W.R., et al. Gastric damage in the rat with nitrogen-containing bisphosphonates depends on pH. Aliment Pharmacol Ther 14 (2000) 1215-1223
22. Kanatsu K., Aihara E., Okayama M., et al. Mucosal irritative and healing impairment action of risedronate in rat stomachs: comparison with alendronate. J Gastroenterol Hepatol 19 (2004) 512-520
23. Peter C.P., Handt L.K., and Smith S.M. Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci 43 (1998) 1998-2002
24. Dobrucali A., Tobey N.A., Awayda M.S., et al. Physiological and morphological effects of alendronate on rabbit esophageal epithelium. Am J Physiol Gastrointest Liver Physiol 283 (2002) G576-G586
25. Lichtenberger L.M., Romero J.J., Gibson G.W., et al. Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 45 (2000) 1792-1801
26. Sener G., Kapucu C., Cetinel S., et al. Gastroprotective effect of leukotriene receptor blocker montelukast in alendronat-induced lesions of the rat gastric mucosa. Prostaglandins Leukot Essent Fatty Acids 72 (2005) 1-11
27. Sener G., Paskaloglu K., Kapucu C., et al. Octreotide ameliorates alendronate-induced gastric injury. Peptides 25 (2004) 115-121
28. Sener G., Sehirli O., Cetinel S., et al. Protective effect of taurine against alendronate-induced gastric damage in rats. Fundam Clin Pharmacol 19 (2005) 93-100
29. Mackay F.J., Wilton L.V., Pearce G.L., et al. United kingdom experience with alendronate and oesophageal reactions. Br J Gen Pract 48 (1998) 1161-1162
30. Abdelmalek M.F., and Douglas D.D. Alendronate-induced ulcerative esophagitis. Am J Gastroenterol 91 (1996) 1282-1283
31. Cameron R.B. Esophagitis dissecans superficialis and alendronate: case report. Gastrointest Endosc 46 (1997) 562-563
32. Ribeiro A., DeVault K.R., Wolfe III J.T., et al. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 47 (1998) 525-528
33. Abraham S.C., Cruz-Correa M., Lee L.A., et al. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol 12 (1999) 1152-1157
34. Valean S., Petrescu M., Catinean A., et al. Pill esophagitis. Rom J Gastroenterol 14 (2005) 159-163
35. Graham D.Y., and Malaty H.M. Alendronate gastric ulcers. Aliment Pharmacol Ther 13 (1999) 515-519
36. Marshall J.K., Rainsford K.D., James C., et al. A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. Aliment Pharmacol Ther 14 (2000) 1451-1457
37. Graham D.Y., Malaty H.M., and Goodgame R. Primary amino-bisphosphonates: a new class of gastrotoxic drugs-comparison of alendronate and aspirin. Am J Gastroenterol 92 (1997) 1322-1325
38. Lowe C.E., Depew W.T., Vanner S.J., et al. Upper gastrointestinal toxicity of alendronate. Am J Gastroenterol 95 (2000) 634-640
39. Lanza F., Rack M.F., Simon T.J., et al. Effects of alendronate on gastric and duodenal mucosa. Am J Gastroenterol 93 (1998) 753-757
40. Bauer D.C., Black D., Ensrud K., et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160 (2000) 517-525
41. Schnitzer T., Bone H.G., Crepaldi G., et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate once-weekly study group. Aging (Milano) 12 (2000) 1-12
42. Lanza F., Sahba B., Schwartz H., et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol 97 (2002) 58-64
43. Greenspan S., Field-Munves E., Tonino R., et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 77 (2002) 1044-1052
44. Eisman J.A., Rizzoli R., Roman-Ivorra J., et al. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 20 (2004) 699-705
45. Graham D.Y., and Malaty H.M. Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 161 (2001) 107-110
46. Cryer B., Miller P., Petruschke R.A., et al. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. Aliment Pharmacol Ther 21 (2005) 599-607
47. Thomson A.B., Marshall J.K., Hunt R.H., et al. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by helicobacter pylori status. J Rheumatol 29 (2002) 1965-1974
48. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA 282 (1999) 1344-1352
49. Reginster J., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 11 (2000) 83-91
50. Lanza F.L., Hunt R.H., Thomson A.B., et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 119 (2000) 631-638